Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020205897 - SYSTEM AND METHOD FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO A TREATMENT REGIMEN

Publication Number WO/2020/205897
Publication Date 08.10.2020
International Application No. PCT/US2020/026042
International Filing Date 31.03.2020
IPC
G01N 33/50 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
A61K 31/712 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7068 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61P 31/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
C07K 14/16 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
16HIV-1
G01N 30/02 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
30Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
02Column chromatography
Applicants
  • URSURE, INC. [US]/[US]
Inventors
  • KARDOS, Keith
  • DAUGHTRIDGE, Giffin
Agents
  • GREENWALD, Eric P.
Priority Data
62/827,34201.04.2019US
62/925,54324.10.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SYSTEM AND METHOD FOR DETECTING THERAPEUTIC AGENTS TO MONITOR ADHERENCE TO A TREATMENT REGIMEN
(FR) SYSTÈME ET MÉTHODE DE DÉTECTION D'AGENTS THÉRAPEUTIQUES POUR SURVEILLER L'ADHÉSION À UN SCHÉMA THÉRAPEUTIQUE
Abstract
(EN)
The disclosure provides methods, kits and systems for detecting a metabolite that is metabolized from a nucleotide reverse transcriptase inhibitor in a biological sample obtained from a subject, and uses thereof in monitoring adherence to pre-exposure prophylaxis and counseling subjects who are engaged in or prescribed pre-exposure prophylaxis. The present disclosure also provides methods of preventing HIV infection in patients at risk of contracting infection by monitoring adherence to a regimen and adjusting or modifying the dosing schedule of the regimen accordingly. The metabolite may be detected using proteomic methods, including but not limited to antibody based methods, such as a lateral flow immunoassay or lab based assays such as semi-quantitative LC-MS/MS.
(FR)
L'invention concerne des procédés, des kits et des systèmes pour détecter un métabolite qui est métabolisé à partir d'un inhibiteur de la transcriptase inverse nucléotidique dans un échantillon biologique obtenu à partir d'un sujet, et des utilisations de ceux-ci pour surveiller le respect d’une prophylaxie pré-exposition et conseiller des sujets qui suivent une prophylaxie pré-exposition prescrite ou qui se voient prescrire une telle prophylaxie. La présente invention concerne également des procédés de prévention d'une infection par le VIH chez des patients présentant un risque de contracter une infection en contrôlant le respect d'un schéma thérapeutique et en ajustant ou en modifiant le schéma posologique du schéma thérapeutique en conséquence. Les métabolites peuvent être identifiés à l'aide de procédés protéomiques, notamment, mais pas exclusivement, des procédés à base d'anticorps, tels qu'un test immunologique à écoulement latéral ou des tests en laboratoire tels qu'une LC-MS/MS semi-quantitative.
Latest bibliographic data on file with the International Bureau